BridgeBio Pharma, Inc. — Director's Dealing 2020

May 21, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-05-19

Reporting Person: Turtle Cameron (See Remarks)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-05-19	Stock Option (Right to Buy)	$1.25	A	1082	Acquired	2027-08-23	Common Stock (1082)	Direct
2020-05-19	Stock Option (Right to Buy)	$0.16	A	74042	Acquired	2029-05-23	Common Stock (74042)	Direct
2020-05-19	Stock Option (Right to Buy)	$0.34	A	49766	Acquired	2029-07-14	Common Stock (49766)	Direct

Footnotes

F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in privately-held subsidiaries of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio.